Clinical trial · Interventional
Docetaxel Versus Oxaliplatin as Addition to S-1 for Stage II / III Gastric Adenocarcinoma
S-1 Plus Docetaxel(DS) Versus S-1 Plus Oxaliplatin(SOX) as Postoperative Therapy for Stage II / III Gastric Cancer, a Randomized Controlled Trial
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
S-1 plus oxaliplatin has been proved better than S-1 alone for stage II or III gastric cancer. Docetaxel also showed excellent efficacy with S-1 in the postoperative setting for stage III gastric cancer. This trial is designed to investigate the efficacy and safety of S-1 plus docetaxel versus S-1 plus oxalipltin as adjuvant chemotherapy after D2 resection in stage II / III gastric cancer.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Gastric Cancer | Malignant Gastric Neoplasm | CURATED_BROADER | 0.80 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Docetaxel | Drug | Docetaxel | ALIAS |
| Oxaliplatin | Drug | Oxaliplatin | ALIAS |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- DS
- description
- D2 resection -- S1 \* 1 cycle + DS \* 6 cycles + S1 \* 9 cycles
- interventionNames
- Drug: Docetaxel
- type
- ACTIVE_COMPARATOR
- label
- SOX
- description
- D2 resection -- SOX \* 8 cycles + S1 \* 8 cycles
- interventionNames
- Drug: Oxaliplatin
Primary outcomes (1)
- measure
- disease-free survival
- timeFrame
- 3 year
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria: * informed consensus of patients * be able to receive oral administration * from 18 to 75 years old * be proven to be primary adenocarcinoma of stomach and staged II or III by pathological evidences * without other chemotherapy and/or radiation against to the disease * normal function of other organs including heart,liver ,kidney and so on * Eastern Cooperative Oncology Group performance status:0\~2 Exclusion Criteria: * history of other malignancy * allergic reaction to S-1 or oxaliplatin of docetaxel * be enrolling in other clinical trials * abnormal GI tract function * dysfunction of other organs * female in pregnancy or lactation,or refuse to receive Contraception measures during chemotherapy * other situation to be judged not adaptive to the study by investigators
References
Publications (0)
Data not yet available